menu
    • menu
    [{"orgOrder":0,"company":"Hanlim Pharmaceuticals Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Risedronate Sodium","moa":"Farnesyl diphosphate synthase","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Hanlim Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hanlim Pharmaceuticals Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Hanlim Pharmaceuticals Inc \/ Undisclosed"},{"orgOrder":0,"company":"Hanlim Pharmaceuticals Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Risedronate Sodium","moa":"Farnesyl diphosphate synthase","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Hanlim Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hanlim Pharmaceuticals Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Hanlim Pharmaceuticals Inc \/ Undisclosed"},{"orgOrder":0,"company":"Hanlim Pharmaceuticals Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Risedronate Sodium","moa":"Farnesyl diphosphate synthase","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Hanlim Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hanlim Pharmaceuticals Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hanlim Pharmaceuticals Inc \/ Undisclosed"},{"orgOrder":0,"company":"Hospital for Special Surgery, New York","sponsor":"The New York Community Trust | East River Medical Imaging | Northwell Health","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Risedronate Sodium","moa":"Farnesyl diphosphate synthase","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Hospital for Special Surgery, New York","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hospital for Special Surgery, New York \/ The New York Community Trust | East River Medical Imaging | Northwell Health","highestDevelopmentStatusID":"11","companyTruncated":"Hospital for Special Surgery, New York \/ The New York Community Trust | East River Medical Imaging | Northwell Health"},{"orgOrder":0,"company":"Warner Chilcott Company, LLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Risedronate Sodium","moa":"Farnesyl diphosphate synthase","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Warner Chilcott Company, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Warner Chilcott Company, LLC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Warner Chilcott Company, LLC \/ Undisclosed"},{"orgOrder":0,"company":"Columbia University","sponsor":"Alliance for Better Bone Health","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Risedronate Sodium","moa":"Farnesyl diphosphate synthase","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Columbia University","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Columbia University \/ Alliance for Better Bone Health","highestDevelopmentStatusID":"10","companyTruncated":"Columbia University \/ Alliance for Better Bone Health"},{"orgOrder":0,"company":"Dong-A ST Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Risedronate Sodium","moa":"Farnesyl diphosphate synthase","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Dong-A ST Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dong-A ST Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Dong-A ST Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"EA Pharma","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Risedronate Sodium","moa":"Farnesyl diphosphate synthase","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"EA Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"EA Pharma \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"EA Pharma \/ Eisai"}]

    Find Clinical Drug Pipeline Developments & Deals for Risedronate Sodium

    Menu

    Risedronate Sodium

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Dong-A ST Co., Ltd.

                            South Korea arrow
                            AAPS
                            Not Confirmed

                            Dong-A ST Co., Ltd.

                            South Korea arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Risedronate Sodium

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety of Actonel® After Denosumab Discontinuation in Postmenopausal Osteoporosis Women

                            Details : Risedronate Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Osteoporosis, Postmenopausal.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 30, 2022

                            Lead Product(s) : Risedronate Sodium

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            EA Pharma

                            France arrow
                            AAPS
                            Not Confirmed

                            EA Pharma

                            France arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Risedronate Sodium

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Approved FDF

                            Sponsor : Eisai

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            All-case Surveillance Condition for Approval of “Actonel® 17.5 mg tablets” for Treatment of Paget’s Dis...

                            Details : Actonel (risedronate sodium hydrate) tablet act as inhibits osteoclasts, which is indicated for the treatment of Paget’s disease and treatment and prevention of postmenopausal osteoporosis.

                            Product Name : Actonel

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 19, 2020

                            Lead Product(s) : Risedronate Sodium

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Approved FDF

                            Sponsor : Eisai

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Hospital for Special Surgery, New York

                            Country arrow
                            AAPS
                            Not Confirmed

                            Hospital for Special Surgery, New York

                            Country arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Risedronate Sodium

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase IV

                            Sponsor : The New York Community Trust | East River Medical Imaging | Northwell Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effects of Bisphosphonates on OI-Related Hearing Loss

                            Details : Risedronate is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Osteogenesis Imperfecta.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 05, 2019

                            Lead Product(s) : Risedronate Sodium

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase IV

                            Sponsor : The New York Community Trust | East River Medical Imaging | Northwell Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Hanlim Pharmaceuticals Inc

                            South Korea arrow
                            AAPS
                            Not Confirmed

                            Hanlim Pharmaceuticals Inc

                            South Korea arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Risedronate Sodium

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            To Evaluate the Efficacy and the Safety of Monthly Versus Weekly Oral Risedronate With Vitamin D in Compliance...

                            Details : Risedronate is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Osteoporosis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 22, 2013

                            Lead Product(s) : Risedronate Sodium

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Hanlim Pharmaceuticals Inc

                            South Korea arrow
                            AAPS
                            Not Confirmed

                            Hanlim Pharmaceuticals Inc

                            South Korea arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Risedronate Sodium

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Post-menopausal Women Osteoporosis(Phase III)

                            Details : Risedronate is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Osteoporosis, Postmenopausal.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 07, 2013

                            Lead Product(s) : Risedronate Sodium

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Hanlim Pharmaceuticals Inc

                            South Korea arrow
                            AAPS
                            Not Confirmed

                            Hanlim Pharmaceuticals Inc

                            South Korea arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Risedronate Sodium

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety Study of Risedronate, Cholecalciferol Combination Tablet in Patients With Osteoporosis

                            Details : Risedronate is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Osteoporosis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 29, 2012

                            Lead Product(s) : Risedronate Sodium

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Columbia University

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Columbia University

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Risedronate Sodium

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase III

                            Sponsor : Alliance for Better Bone Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Combination Risedronate - Parathyroid Hormone Trial in Male Osteoporosis

                            Details : Risedronate is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Osteoporosis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 05, 2012

                            Lead Product(s) : Risedronate Sodium

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase III

                            Sponsor : Alliance for Better Bone Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Warner Chilcott Company, LLC

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Warner Chilcott Company, LLC

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Risedronate Sodium

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of Stopping Risedronate After Long Term Treatment on Bone Turnover

                            Details : Risedronate is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Osteoporosis, Postmenopausal.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 29, 2010

                            Lead Product(s) : Risedronate Sodium

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth